Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 16, Issue 3 (May 2014) 16, 348–353; 10.4103/1008-682X.127812

Radium‑223 in metastatic castration resistant prostate cancer

Winston Vuong1, Oliver Sartor2, Sumanta K Pal1

1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA; 2Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.

Correspondence: Correspondence: Dr. SK Pal (spal@coh.org)

Received: 04 December 2013; Revised: 10 February 2014; Accepted: 11 February 2014

Abstract

In 2004, docetaxel was approved for the treatment of metastatic castration‑resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals. However, from 2010 onwards, 5 additional therapies have been approved on the basis of showing a survival benefit in phase III studies. These agents include sipuleucel‑T, cabazitaxel, abiraterone, enzalutamide and (most recently) radium‑223. Amongst radiopharmaceuticals currently used for advanced prostate cancer (e.g. samarium‑153 and strontium‑89), radium‑223 possesses several unique properties. As an alpha‑emitting compound, the agent produces a high‑energy output over a short range, facilitating selective destruction of tissue within the bone in the region of osteoblastic lesions while sparing surrounding normal tissue. The current review will outline biological rationale for radium‑223 and also provide an overview of preclinical and clinical development of the agent. Rational sequencing of radium‑223 and combinations, in the increasingly complex landscape of mCRPC will be discussed, along with factors influencing clinical implementation.

Keywords: alpharadin; bone metastases; metastatic castration‑resistant prostate cancer; radiopharmaceuticals; radium‑223; Xofigo 1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA; 2Depart

Full Text | PDF | 中文摘要 |

 
Browse:  2287
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved